We are very pleas Professor Shi Yuankai, the principal investigator of the riortinib clinical trial and the Cancer Hospital of
the Chinese Academy of Mical Sciences, said: “Riortinib tablets have shown excellent efficacy and
safety in patients with NSCLC who have progress on firstgeneration or secondgeneration EGFRTKI
treatment, EGFR T790M mutationpositive patients, and fax lists patients who are firstline treatment for
NSCLC with EGFR sensitive mutations, with outstanding efficacy in brain metastases. Its successful
approval will bring more treatment options and hope to the vast number of Chinese patients with advanc EGFR mutationpositive NSCLC.”
Dr. Hui Zhou , Senior Vice President of Innovent Biologics, said:
“(Riertinib Tablets has been successfully approv, providing a new treatment option for a wide range of
lung cancer patients with T790M mutations after EGFRTKI resistance. We also look forward to the
approval of firstline indications in the near future to benefit more patients. As the 14th commercial
product of Innovent Biologics, Aoyixin® ( Riertinib Tablets also marks an important step for us in the
field of precision micine for lung cancer. We look forward to working together with Aosaikang
Pharmaceutical to make Aoyixin® ( Riertinib Tablets bring new treatment hope to NSCLC patients with EGFR mutations.”
Ma Jingfei, Director and General Manager of Aosaikang Pharmaceuticals, said:
In addition to the approv indication for EGFR T790M mutationpositive NSCLC, Aoyixin® ( Riertinib
Tablets has also submitt an NDA application acd automatic incoming call distribution device for the firstline indication for EGFR sensitive
mutationpositive NSCLC. Aosaikang has also develop an innovative project ASKC202, a highly
selective cMet inhibitor, which is currently undergoing clinical studies in combination with Riertinib
Tablets for the treatment of patients resistant mobile lead to the thirdgeneration EGFRTKI. We look forward to
the fact that in the near future, with the help of Innovent Biologics, Aoyixin® ( Riertinib Tablets will benefit more Chinese lung cancer patients. As Aoyixin® ‘s first approv Class 1 innovative drug for marketing, it marks an important progress in the company’s transformation to innovative drug research and development We are very pleas.